bullish
Abbott Laboratories (ABT US): Beat-And-Raise Q2; Nutrition Drags; Full-Year EPS Guidance Raised
351 Views21 Jul 2022 19:50
SUMMARY
- Abbott Laboratories (ABT US) reported strong Q2 results, thanks to higher-than-expected COVID-19 test-related sales of $2.3 billion. However, base business remained muted due to nutrition product recall and manufacturing shutdown.
- FreeStyle Libre revenue grew 19% y/y to $1.1 billion in the quarter, with a global user base exceeding 4 million. Abbott received FDA approval for FreeStyle Libre 3 system.
- The company has raised 2022 EPS guidance 4% to $4.90 and ahead of consensus. COVID testing revenue guidance was also raised by 36% to $6.1 billion.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Abbott Laboratories (ABT US): Beat-And-Raise Q3; COVID Testing Sales Dragged; Shares Hit 52-Week Low20 Oct 2022
- Abbott Laboratories (ABT US): 2022 High Conviction Idea 1Q22 Review- COVID Testing Bonanza Continues21 Apr 2022
- Abbott Laboratories (ABT US): Q42021 Review- Conservative Guidance Leaves Room For Upside Potential27 Jan 2022
- 2022 High Conviction: Abbott Laboratories – Resilient Business Model at Reasonable Valuation02 Dec 2021
x